Here's a new threat to Lucentis, the eye drug from Roche ($RHHBY) and Novartis ($NVS). British doctors are calling for the National Health Service to routinely use Roche's cancer med Avastin to treat patients with wet age-related macular degeneration, rather than the much costlier Lucentis. The two drugs work in a similar fashion and some studies show they work equally well for eye problems, but Avastin isn't licensed for use in the eye. Report